Takeaways: Quebec’s listing of PrOKEDI on the RAMQ formulary is a key commercial milestone for Bausch Health, turning a specialized, once‑monthly long‑acting risperidone into a publicl...
Takeaways: The pCPA Letter of Intent for PrOKEDI (risperidone LAI) moves Bausch Health toward public reimbursement and broader access for Canada’s schizophrenia population, w...
Takeaways Optimi is using its Nasdaq uplist and 1‑for‑30 share consolidation to raise roughly 15 million US dollars at scale, then plow the cash into making and selling ...
